Pelvic Exenteration in Elderly Individuals with Advanced Cancer
Authors/Creators
- 1. Assistant Professor, Department of General Surgery, SCB Medical College and Hospital, Cuttack, Odisha, India
- 2. Assistant Professor, Department of Ostetrics and Gynaecology, Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha, India
- 3. Assistant Professor, Department of General Medicine, Shree Jagannath Medical College and Hospital, Puri, Odisha, India
Description
Background: An invasive surgical operation, pelvic exenteration is only appropriate for a very restricted group of patients. Elderly patients who have surgery frequently have higher rates of morbidity and mortality. Examining the results of exenteration for advanced pelvic cancer in this patient subgroup was the goal of this investigation. Methods: The study included all patients who underwent pelvic exenteration between ‘January 2018 to January 2019’ and were at least 70 years old. This included all primary tumors of the bladder, gynaecological system, and rectal area. The 5-year overall survival was the main outcome measure. Post-operative morbidity and 30-day death were the secondary objectives. Results: There were 80 patients in all, ranging in age from 70 to 90 years old, with a median age of 75. Eight bladder tumors, 30 gynaecological, and 42 rectal tumors were found. The way that neoadjuvant therapy was administered varied significantly depending on the type of tumor. Within 30 days following surgery, five patients (5%) died and 30 patients (33%) experienced postoperative problems. Patients with rectal cancer had a median survival of 64 months, gynaecological tumor patients had a median survival of 30 months, and bladder cancer patients had a median survival of 15 months. The five-year survival rates for each of these groups were, respectively, 46, 30, and 21%.
Abstract (English)
Background: An invasive surgical operation, pelvic exenteration is only appropriate for a very restricted group of patients. Elderly patients who have surgery frequently have higher rates of morbidity and mortality. Examining the results of exenteration for advanced pelvic cancer in this patient subgroup was the goal of this investigation. Methods: The study included all patients who underwent pelvic exenteration between ‘January 2018 to January 2019’ and were at least 70 years old. This included all primary tumors of the bladder, gynaecological system, and rectal area. The 5-year overall survival was the main outcome measure. Post-operative morbidity and 30-day death were the secondary objectives. Results: There were 80 patients in all, ranging in age from 70 to 90 years old, with a median age of 75. Eight bladder tumors, 30 gynaecological, and 42 rectal tumors were found. The way that neoadjuvant therapy was administered varied significantly depending on the type of tumor. Within 30 days following surgery, five patients (5%) died and 30 patients (33%) experienced postoperative problems. Patients with rectal cancer had a median survival of 64 months, gynaecological tumor patients had a median survival of 30 months, and bladder cancer patients had a median survival of 15 months. The five-year survival rates for each of these groups were, respectively, 46, 30, and 21%.
Files
IJPCR,Vol15,Issue12,Article49.pdf
Files
(344.1 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:432a1ff1812c14a3cbabd081b82b1e2a
|
344.1 kB | Preview Download |
Additional details
Dates
- Accepted
-
2023-09-20
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/15/IJPCR,Vol15,Issue12,Article49.pdf
- Development Status
- Active
References
- 1. Radwan RW, Jones HG, Rawat N, Davies M, Evans MD, Harris DA et al.; Swansea Pelvic Oncology Group. Determinants of survival following pelvic exenteration for primary rectal cancer. Br J Surg 2015; 102: 1278–1284. 2. World Health Organization. Definition of an Older or Elderly Person. http://www.who.int/ healthinfo/survey/ageingdefnolder/en/[accesse d17 July 2015]. 3. National Cancer Intelligence Network (NCIN). Older People and Cancer (version 3.0). http:// www.ncin.org.uk/publications/older_ people_ and0020_0020cancer [accessed 17 July 2015]. 4. Griffiths R, Beech F, Brown A, Dhesi J, Foo I, Goodall J. Peri-operative care of the elderly 2014: Association of Anaesthetists of Great Britain and Ireland. Anaesthesia 2014; 69 (Su pp0020l 1): 81–98. 5. McCarthy K, Pearson K, Fulton R, Hewitt J. Pre-operative chemoradiation for nonmetastatic locally advanced rectal cancer. Cochrane Database Syst Rev 2012; (12)CD00 8368. 6. Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg 2012; 99: 918–928. 7. Vaughn DJ. Chemotherapeutic options for cisplatin-ineligible patients with advancedcarcinoma of the urothelium. Cancer Treat Rev 2008; 34: 328–338. 8. Harris DA, Davies M, Lucas MG, Drew P, Carr ND, Beynon J et al. Multivisceral resection for primary locally advanced rectal carcinoma. Br J Surg 2011; 98: 582–588. 9. Kusters M, Austin KK, Solomon MJ, Lee PJ, Nieuwenhuijzen GA, Rutten HJ. Survival after pelvic exenteration for T4 rectal cancer. Br J Surg 2015; 102: 125–131. 10. Williamson JS, Jones HG, Davies M, Evans MD, Hatcher O, Beynon J et al.; Swansea Colorectal Cancer Group. Outcomes in locally advanced rectal cancer with highly selective preoperative chemoradiotherapy. Br J Surg 201 4; 101: 1290–1298.